Renal Outcomes Associated with the Use of Non-Insulin Antidiabetic Pharmacotherapy: A Review of Current Evidence and Recommendations

References

• WHO. Global report on diabetes. 2016 Available from: http://www.who.int/about/licensing/copyright_form/index.html. Accessed 917, 2020.
   Google Scholar
• De Boer IH. Kidney disease and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care. 2014;37(1):24–30. doi:10.2337/dc13-211324356594
   PubMed Web of Science ®Google Scholar
• Gross JL, De Azevedo MJ, Silveiro SP, et al. Diabetic nephropathy: diagnosis, prevention, and treatment. Diabetes Care. 2005;28:176–188. doi:10.2337/diacare.28.1.164
   Web of Science ®Google Scholar
• Williams DM, Nawaz A, Evans M. Renal outcomes in type 2 diabetes: a review of cardiovascular and renal outcome trials. Diabetes Ther. 2020;11(2):369–386. doi:10.1007/s13300-019-00747-331863343
   PubMed Web of Science ®Google Scholar
• Buse JB, Wexler DJ, Tsapas A, et al. 2019 update to: management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care. 2020;43(2):487–493. doi:10.2337/dci19-006631857443
   PubMed Web of Science ®Google Scholar
• Sung K-C, Ryu S, Lee J-Y, et al. Urine albumin/creatinine ratio below 30 mg/g is a predictor of incident hypertension and cardiovascular mortality. Am Hear Assoc. 2016;5(9). doi:10.1161/JAHA.116.003245
   Google Scholar
• Gerstein HC, Mann JFE, Yi Q, et al. Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. J Am Med Assoc. 2001;286(4):421–426. doi:10.1001/jama.286.4.421
   PubMed Web of Science ®Google Scholar
• Zoungas S, Arima H, Gerstein HC, et al. Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol. 2017;5(6):431–437. doi:10.1016/S2213-8587(17)30104-328365411
   PubMed Web of Science ®Google Scholar
• Bell S, Farran B, McGurnaghan S, et al. Risk of acute kidney injury and survival in patients treated with Metformin: an observational cohort study. BMC Nephrol. 2017;18(1):163. doi:10.1186/s12882-017-0579-528526011
   PubMed Web of Science ®Google Scholar
• Christiansen CF, Ehrenstein V, Heide-Jørgensen U, et al. Metformin initiation and renal impairment: a cohort study in Denmark and the UK. BMJ Open. 2015;5(9):e008531. doi:10.1136/bmjopen-2015-008531
   Web of Science ®Google Scholar
• Ekström N, Schiöler L, Svensson AM, et al. Effectiveness and safety of metformin in 51 675 patients with type 2 diabetes and different levels of renal function: a cohort study from the Swedish national diabetes register. BMJ Open. 2012;2(4):e001076. doi:10.1136/bmjopen-2012-001076
   PubMed Web of Science ®Google Scholar
• Mariano F, Pozzato M, Inguaggiato P, et al. Metformin-associated lactic acidosis undergoing renal replacement therapy in intensive care units: a five-million population-based study in the North-West of Italy. Blood Purif. 2017;44(3):198–205. doi:10.1159/00047191728668963
   PubMed Web of Science ®Google Scholar
• Heerspink HJL, Karasik A, Thuresson M, et al. Kidney outcomes associated with use of SGLT2 inhibitors in real-world clinical practice (CVD-REAL 3): a multinational observational cohort study. Lancet Diabetes Endocrinol. 2020;8(1):27–35. doi:10.1016/S2213-8587(19)30384-531862149
   PubMed Web of Science ®Google Scholar
• Mosenzon O, Wiviott SD, Cahn A, et al. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE–TIMI 58 randomised trial. Lancet Diabetes Endocrinol. 2019;7(8):606–617. doi:10.1016/S2213-8587(19)30180-931196815
   PubMed Web of Science ®Google Scholar
• Fioretto P, Stefansson BV, Johnsson E, Cain VA, Sjöström CD. Dapagliflozin reduces albuminuria over 2 years in patients with type 2 diabetes mellitus and renal impairment. Diabetologia. 2016;59(9):2036–2039. doi:10.1007/s00125-016-4017-127306615
   PubMed Web of Science ®Google Scholar
• Fioretto P, Del Prato S, Buse JB, et al. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment (chronic kidney disease stage 3A): the DERIVE study. Diabetes, Obes Metab. 2018;20(11):2532–2540. doi:10.1111/dom.1341329888547
   PubMed Web of Science ®Google Scholar
• Kadowaki T, Nangaku M, Hantel S, et al. Empagliflozin and kidney outcomes in Asian patients with type 2 diabetes and established cardiovascular disease: results from the EMPA-REG OUTCOME ® trial. J Diabetes Investig. 2019;10(3):760–770. doi:10.1111/jdi.12971
   PubMed Web of Science ®Google Scholar
• Kashiwagi A, Takahashi H, Ishikawa H, et al. A randomized, double-blind, placebo-controlled study on long-term efficacy and safety of ipragliflozin treatment in patients with type 2 diabetes mellitus and renal impairment: results of the long-term ASP1941 safety evaluation in patients with type 2 dia. Diabetes, Obes Metab. 2015;17(2):152–160. doi:10.1111/dom.1240325347938
   PubMed Web of Science ®Google Scholar
• Wanner C, Inzucchi SE, Lachin JM, et al. Empagliflozin and progression of kidney disease in type 2 diabetes. N Engl J Med. 2016;375(4):323–334. doi:10.1056/NEJMoa151592027299675
   PubMed Web of Science ®Google Scholar
• Lambers Heerspink HJ, De Zeeuw D, Wie L, Leslie B, List J. Dapagliflozin a glucose-regulating drug with diuretic properties in subjects with type 2 diabetes. Diabetes, Obes Metab. 2013;15(9):853–862. doi:10.1111/dom.1212723668478
   PubMed Web of Science ®Google Scholar
• Nadkarni GN, Ferrandino R, Chang A, et al. Acute kidney injury in patients on SGLT2 inhibitors: a propensity-matched analysis. Diabetes Care. 2017;40(11):1479–1485. doi:10.2337/dc17-101128827404
   PubMed Web of Science ®Google Scholar
• Mahaffey KW, Jardine MJ, Bompoint S, et al. Canagliflozin and cardiovascular and renal outcomes in type 2 diabetes mellitus and chronic kidney disease in primary and secondary cardiovascular prevention groups: results from the randomized CREDENCE trial. Circulation. 2019;140(9):739–750. doi:10.1161/CIRCULATIONAHA.119.04200731291786
   PubMed Web of Science ®Google Scholar
• Perkovic V, de Zeeuw D, Mahaffey KW, et al. Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS program randomised clinical trials. Lancet Diabetes Endocrinol. 2018;6(9):691–704. doi:10.1016/S2213-8587(18)30141-429937267
   PubMed Web of Science ®Google Scholar
• Yamout H, Perkovic V, Davies M, et al. Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy. Am J Nephrol. 2014;40(1):64–74. doi:10.1159/00036490925059406
   PubMed Web of Science ®Google Scholar
• Cherney DZI, Heerspink HJL, Frederich R, et al. Effects of ertugliflozin on renal function over 104 weeks of treatment: a post hoc analysis of two randomised controlled trials. Diabetologia. 2020;63(6):1128–1140. doi:10.1007/s00125-020-05133-432236732
   PubMed Web of Science ®Google Scholar
• Rosenstock J, Perkovic V, Johansen OE, et al. Effect of linagliptin vs placebo on major cardiovascular events in adults with type 2 diabetes and high cardiovascular and renal risk: the CARMELINA randomized clinical trial. JAMA - J Am Med Assoc. 2019;321(1):69–79. doi:10.1001/jama.2018.18269
   PubMed Web of Science ®Google Scholar
• Groop PH, Cooper ME, Perkovic V, et al. Linagliptin and its effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: the randomized MARLINA-T2D trial. Diabetes, Obes Metab. 2017;19(11):1610–1619. doi:10.1111/dom.1304128636754
   PubMed Web of Science ®Google Scholar
• Kim YG, Byun J, Yoon D, et al. Renal protective effect of DPP-4 inhibitors in type 2 diabetes mellitus patients: a cohort study. J Diabetes Res. 2016;2016:1–9. doi:10.1155/2016/1423191
   Web of Science ®Google Scholar
• Mosenzon O, Leibowitz G, Bhatt DL, et al. Effect of saxagliptin on renal outcomes in the SAVOR-TIMI 53 trial. Diabetes Care. 2017;40(1):69–76. doi:10.2337/dc16-062127797925
   PubMed Web of Science ®Google Scholar
• Scott R, Morgan J, Zimmer Z, et al. A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: the CompoSIT-R study. Diabetes, Obes Metab. 2018;20(12):2876–2884. doi:10.1111/dom.1347330019498
   PubMed Web of Science ®Google Scholar
• von Eynatten M, Gong Y, Emser A, Woerle HJ. Efficacy and safety of linagliptin in type 2 diabetes subjects at high risk for renal and cardiovascular disease: a pooled analysis of six Phase III clinical trials. Cardiovasc Diabetol. 2013;12(1):1–9. doi:10.1186/1475-2840-12-6023280391
   PubMed Web of Science ®Google Scholar
• Cornel JH, Bakris GL, Stevens SR, et al. Effect of sitagliptin on kidney function and respective cardiovascular outcomes in type 2 diabetes: outcomes from TECOS. Diabetes Care. 2016;39(12):2304–2310. doi:10.2337/dc16-141527742728
   PubMed Web of Science ®Google Scholar
• Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and renal outcomes in type 2 diabetes: an exploratory analysis of the REWIND randomised, placebo-controlled trial. Lancet. 2019;394(10193):131–138. doi:10.1016/S0140-6736(19)31150-X31189509
   PubMed Web of Science ®Google Scholar
• Tuttle KR, Lakshmanan MC, Rayner B, et al. Dulaglutide versus insulin glargine in patients with type 2 diabetes and moderate-to-severe chronic kidney disease (AWARD-7): a multicentre, open-label, randomised trial. Lancet Diabetes Endocrinol. 2018;6(8):605–617. doi:10.1016/S2213-8587(18)30104-929910024
   PubMed Web of Science ®Google Scholar
• Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–1844. doi:10.1056/NEJMoa160714127633186
   PubMed Web of Science ®Google Scholar
• Bethel MA, Mentz RJ, Merrill P, et al. Renal outcomes in the EXenatide study of cardiovascular event lowering (EXSCEL). Diabetes. 2019;67(Supplement 1):522. doi:10.2337/db18-522-p
   Web of Science ®Google Scholar
• Mann JFE, Ørsted DD, Brown-Frandsen K, et al. Liraglutide and renal outcomes in type 2 diabetes. N Engl J Med. 2017;377(9):839–848. doi:10.1056/NEJMoa161601128854085
   PubMed Web of Science ®Google Scholar
• Muskiet MHA, Tonneijck L, Huang Y, et al. Lixisenatide and renal outcomes in patients with type 2 diabetes and acute coronary syndrome: an exploratory analysis of the ELIXA randomised, placebo-controlled trial. Lancet Diabetes Endocrinol. 2018;6(11):859–869. doi:10.1016/S2213-8587(18)30268-730292589
   PubMed Web of Science ®Google Scholar
• Chen YH, Tarng DC, Chen HS. Renal outcomes of pioglitazone compared with acarbose in diabetic patients: a randomized controlled study. PLoS One. 2016;11:11. doi:10.1371/journal.pone.0165750
   Web of Science ®Google Scholar
• Van Dalem J, Brouwers MCGJ, Stehouwer CDA, et al. Risk of hypoglycaemia in users of sulphonylureas compared with metformin in relation to renal function and sulphonylurea metabolite group: population based cohort study. BMJ. 2016;354. doi:10.1136/bmj.i3625
   Web of Science ®Google Scholar
• Hsu WH, Hsiao PJ, Lin PC, Chen SC, Lee MY, Shin SJ. Effect of metformin on kidney function in patients with type 2 diabetes mellitus and moderate chronic kidney disease. Oncotarget. 2018;9(4):5416–5423. doi:10.18632/oncotarget.2338729435189
   PubMedGoogle Scholar
• Fioretto P, Zambon A, Rossato M, Busetto L, Vettor R. SGLT2 inhibitors and the diabetic kidney. Diabetes Care. 2016;39(August):S165–S171. doi:10.2337/dcS15-300627440829
   PubMed Web of Science ®Google Scholar
• Margonato D, Galati G, Mazzetti S, et al. Renal protection: a leading mechanism for cardiovascular benefit in patients treated with SGLT2 inhibitors. Heart Fail Rev. 2020:1–9. doi:10.1007/s10741-020-10024-231414215
   PubMed Web of Science ®Google Scholar
• Sarafidis P, Ferro CJ, Morales E, et al. SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA. Nephrol Dial Transplant. 2019;34(2):208–230. doi:10.1093/ndt/gfy40730753708
   PubMed Web of Science ®Google Scholar
• Cosentino F, Grant PJ, Aboyans V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. Eur Heart J. 2020;41(2):255–323. doi:10.1093/eurheartj/ehz48631497854
   PubMed Web of Science ®Google Scholar
• Cahn A, Melzer-Cohen C, Pollack R, Chodick G, Shalev V. Acute renal outcomes with sodium-glucose co-transporter-2 inhibitors: real-world data analysis. Diabetes, Obes Metab. 2019;21(2):340–348. doi:10.1111/dom.1353230207040
   PubMed Web of Science ®Google Scholar
• Elnaem MH, Azam FM, Akkawi ME. Cardiovascular outcomes and the use of oral antidiabetic drugs: a review of current evidence from observational studies. IIUM Med J Malaysia. 2020;19(3):100–110. doi:10.31436/imjm.v19i3.1671
   Google Scholar
• Coppolino G, Leporini C, Rivoli L, et al. Exploring the effects of DPP-4 inhibitors on the kidney from the bench to clinical trials. Pharmacol Res. 2018;129:274–294. doi:10.1016/j.phrs.2017.12.00129223646
   PubMed Web of Science ®Google Scholar
• Kanasaki K. The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin. Clin Sci. 2018;132(4):489–507. doi:10.1042/CS20180031
   Web of Science ®Google Scholar
• Lovshin JA, Rajasekeran H, Lytvyn Y, et al. Dipeptidyl peptidase 4 inhibition stimulates distal tubular natriuresis and increases in circulating sdf-1a1-67 in patients with type 2 diabetes. Diabetes Care. 2017;40(8):1073–1081. doi:10.2337/dc17-006128550195
   PubMed Web of Science ®Google Scholar
• Preston RA. Renoprotective effects of antihypertensive drugs. Am J Hypertens. 1999;12(1SUPPL. 1):19S–32S. doi:10.1016/S0895-7061(98)00210-610077416
   PubMed Web of Science ®Google Scholar
• Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res. 2014;114(11):1788–1803. doi:10.1161/CIRCRESAHA.114.30195824855202
   PubMed Web of Science ®Google Scholar
• Greco EV, Russo G, Giandalia A, Viazzi F, Pontremoli R, De Cosmo S. GLP-1 receptor agonists and kidney protection. Med. 2019;55(6):233. doi:10.3390/medicina55060233
   Web of Science ®Google Scholar
• Kawanami D, Takashi Y. GLP-1 receptor agonists in diabetic kidney disease: from clinical outcomes to mechanisms. Front Pharmacol. 2020;11. doi:10.3389/fphar.2020.00967
   Web of Science ®Google Scholar
• Moen MF, Zhan M, Hsu VD, et al. Frequency of hypoglycemia and its significance in chronic kidney disease. Clin J Am Soc Nephrol. 2009;4(6):1121–1127. doi:10.2215/CJN.0080020919423569
   PubMed Web of Science ®Google Scholar
• Alsahli M, Gerich J. Hypoglycemia in patients with diabetes and renal disease. J Clin Med. 2015;4(5):948–964. doi:10.3390/jcm405094826239457
   PubMed Web of Science ®Google Scholar
• Muskiet MHA, Tonneijck L, Smits MM, et al. GLP-1 and the kidney: from physiology to pharmacology and outcomes in diabetes. Nat Rev Nephrol. 2017;13(10):605–628. doi:10.1038/nrneph.2017.12328869249
   PubMed Web of Science ®Google Scholar
• Marso SP, Daniels GH, Frandsen KB, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–322. doi:10.1056/NEJMoa160382727295427
   PubMed Web of Science ®Google Scholar
• American Diabetes Association. Standards of medical care in diabetes-2020. Diabetes Care. 2020;43(1). doi:10.2337/diacare.29.02.06.dc05-1593
   Web of Science ®Google Scholar
• Berbari AE. Links between chronic kidney disease and cardiovascular disease: a bidirectional relationship In: Cardiorenal Syndrome: Mechanisms, Risk and Treatment. Springer Milan; 2010:3–14. doi:10.1007/978-88-470-1463-3_1
   Google Scholar